fbpx
X
Notice: You have clicked on a link which leaves Fresenius Kabi’s website and you will be redirected to a third-party website. Fresenius Kabi makes no representations nor has any supervision or control over the quality, content, reliability, or security of the third-party website, nor shall Fresenius Kabi be liable for its use.
Continue Cancel
Profile view of a thoughtful male doctor wearing a white coat against a dark blue background.

4 oils in 1 lipid emulsion: see the difference

As the US market leader in lipid injectable emulsions (ILEs),1 we’re proud to offer SMOFlipid® (lipid injectable emulsion), for intravenous use, as an option for parenteral nutrition (PN). With its unique blend, SMOFlipid demonstrates our commitment to providing an alternative to soybean oil ILEs, helping to support the nutrition needs of patients at any age.2

Designed with more oils for a balanced fatty acid profile

A source of calories and essential fatty acids (EFAs) for PN, SMOFlipid nourishes patients—from stable to critically and chronically ill—with a one-of-a-kind blend of 4 oil sources.2

Dropper with different lipid sources

SMOFlipid’s unique blend of 4 oils allows clinicians to provide daily lipids for patients requiring PN.2

Indicated for daily lipid dosing2

Daily lipids can be a part of PN because they provide EFAs and are an alternative to dextrose as a sole energy source, which can help minimize the complications of excessive dextrose administration, including hepatic steatosis, respiratory insufficiency, hyperglycemia-induced compromised immune function, metabolic stress, and fever.5,6

Purple circular badge with a colorful four-petal icon in the center and text promoting daily lipid dosing recommendations for adults.

Infographic on daily lipid dosing recommendations for pediatric patients, featuring a colorful flower-shaped icon and purple circular design.

Recommended dosage depends on age, energy expenditure, clinical status, body weight, tolerance, ability to metabolize and eliminate lipids, and consideration of additional energy given to the patient.2
Do not exceed the maximum infusion rate of 0.5 mL/kg/hour in adults and 0.75 mL/kg/hour in pediatrics.2

Please refer to the Full Prescribing Information for complete dosing guidance.

Contains EFAs to support EFA needs2

SMOFlipid contains linoleic acid (LA) and alpha-linolenic acid (ALA), which are precursors to long-chain polyunsaturated fatty acids (LCPUFAs) that help prevent essential fatty acid deficiency (EFAD)2,8,9:

  • LA is an omega-6 FA and precursor to arachidonic acid (ARA)
  • ALA is an omega-3 FA and precursor to EPA and DHA
Essential Fatty Acid Deficiency: Monitor for signs and symptoms; monitor laboratory parameters.2
Proven to have a well-established safety and tolerability profile2

The US Food and Drug Administration (FDA) approved SMOFlipid for adults in 2016; six years later in 2022, SMOFlipid received approval for use in pediatric patients, including term and preterm neonates.2

There has been a recent publication from a post-marketing study.10 Read the full article.

SMOFlipid is a trusted lipid for the top 10 children’s hospitals*†

*Data on file 3/1/25.
†As reported by US News & World Report: https://health.usnews.com/best-hospitals/pediatric-rankings

SMOFlipid has been extensively researched, including in studies in more than 175 adult patients in 3 clinical trials and in more than 170 pediatric patients in 4 randomized, active-controlled, double-blind, parallel-group controlled clinical trials.2

In addition, Fresenius Kabi has developed comprehensive admixture stability and Y-site drug compatibility reference guides to help ensure the stability, compatibility, and integrity of admixtures for adult and pediatric patients. Check them out here.

Discover the one and only SMOFlipid

SMOFlipid is globally recognized, with approval in more than 75 countries. This unique blend of 4 oil sources provides a source of calories and EFAs to help nourish adult and pediatric patients requiring PN.2

Learn more about SMOFlipid:

For Adults

For Pediatrics

SMOFlipid® (lipid injectable emulsion, USP), for intravenous use IMPORTANT SAFETY INFORMATION

What is SMOFlipid?

  • Indicated in adult and pediatric patients as a source of calories and essential fatty acids for parenteral nutrition (PN) when oral or enteral nutrition is not possible, insufficient, or contraindicated.
  • The hourly infusion rate in pediatrics should not exceed 0.75 mL/kg/hour and 0.5 mL/kg/hour in adults.

SMOFlipid should not be received by patients who have:

  • A known allergy to fish, egg, soybean, or peanut, or to any of the active or inactive ingredients in SMOFlipid.
  • Abnormally high levels of lipid (triglycerides) in the blood.

SMOFlipid may cause serious side effects including:

  • Serious Adverse Reactions with Rapid Infusion of Intravenous Lipid Emulsion in Neonates and Infants: Strictly follow the recommended total daily dosage and do not exceed the maximum infusion rate. If poor clearance of fats occurs, the infusion should be stopped, and a medical evaluation started.
  • Risk of Parenteral Nutrition-Associated Liver Disease: Parenteral nutrition-associated liver disease (PNALD) may progress to liver inflammation and damage caused by a buildup of fat in the liver with scarring and cirrhosis.
  • Allergic Reactions: Contact your healthcare provider immediately if you are experiencing an allergic reaction.
  • Fat Overload Syndrome, Refeeding Syndrome, Elevated Triglycerides (Hypertriglyceridemia): Your healthcare provider will monitor you for signs and symptoms of early infection and blood levels.

Monitoring/Laboratory Tests: The content of vitamin K may interfere with blood clotting activity of medications.

The most common side effects (>1%) in adult patients include nausea, vomiting, and high levels of glucose in the blood and in pediatric patients include low levels of red blood cells, vomiting, increased levels of liver enzymes (i.e., gamma-glutamyltransferase) and hospital- acquired infections.

These are not all the possible side effects associated with SMOFlipid. Call your healthcare provider for medical advice regarding SMOFlipid side effects. You are encouraged to report negative side effects of SMOFlipid. Contact Fresenius Kabi USA, LLC at: 1-800-551-7176 or FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch. The FDA-approved product labeling can be found at https://freseniuskabinutrition.com/SMOFlipidPI.

If you still can't find what you're looking for regarding our PN products or Fresenius Kabi Nutrition, let us know and we can help.

Contact us

Sources: 1. Data on File; 3/1/25; calculation includes: all ILEs approved in the US. 2. SMOFlipid Prescribing Information, Fresenius Kabi USA, LLC. 2023. 3. Kalish BT, Fallon EM, Puder M. A tutorial on fatty acid biology. JPEN J Parenter Enteral Nutr. 2012;36(4):380-388. 4. Deckelbaum RJ, Hamilton JA, Moser A, et al. Medium-chain versus long-chain triacylglycerol emulsion hydrolysis by lipoprotein lipase and hepatic lipase: implications for the mechanisms of lipase action. Biochemistry. 1990;29(5):1136-1142. 5. Vanek VW, Seidner DL, Allen P, et al. A.S.P.E.N. position paper: Clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150-192. 6. Calder PC, Jensen GL, Koletzko BV, Singer P, Wanten GJ. Lipid emulsions in parenteral nutrition of intensive care patients: current thinking and future directions. Intensive Care Med. 2010;36(5):735-749. 7. ASPEN Lipid Injectable Emulsion Safety Recommendations for Adult Patients. ASPEN website. 2021. Accessed March 4, 2025. https://nutritioncare.org/wp-content/uploads/2024/12/ILE-Safety-Recommendations-Adult.pdf 8. Agostoni C. Role of long-chain polyunsaturated fatty acids in the first year of life. J Pediatr Gastroenterol Nutr. 2008;47 Suppl 2:S41-S44. 9. Fell GL, Nandivada P, Gura KM, Puder M. Intravenous Lipid Emulsions in Parenteral Nutrition. Adv Nutr. 2015;6(5):600-610. Published 2015 Sep 15. 10. Abrams SA, Ernst KD, Weitkamp JH, et al. Safety and Efficacy of a Composite Lipid Emulsion with Fish Oil in Hospitalized Neonates and Infants Requiring Prolonged Parenteral Nutrition – A Randomized, Double-Blind, Multicenter, Controlled Trial. J Nutr. 2024;154(12):3615-3625.